Groups: (Hardly‽) overlapping CIs [Design Issues]

posted by Helmut Homepage – Vienna, Austria, 2024-11-22 13:58 (194 d 01:44 ago) – Posting: # 24292
Views: 4,284

Hi BEQool,

❝ […] Unfortunately, these kind of deficiency questions will probably become inevitable when conducting a study in groups.

Quite likely, esp. since agencies think that \(\small{p(G\times T)<0.05}\) is a signal of data manipulation.

❝ ❝ […] a separate exploratory analysis of each group was performed and produced the following outcomes

❝ Did you perform this exploratory analysis of each group or did the agency do it?

The applicant did.

❝ ❝ Therefore, the applicant should provide a justification for this difference and discuss its potential impact on the conclusion of bioequivalence.

↑ This was a request of the agency.

❝ ❝ A new term: Hardly overlapping CIs. Again: So what? Justification?

❝ How do you plan to "justify" this difference?

Well, the deadline for the response is today. I made only sarcastic comments like …

As long as confidence limits overlap, treatment effects estimated in the groups do not differ significantly. To question that is like saying “since the upper confidence limit is 124%, products are hardly bioequivalent”

… and suggested the applicant to translate it into a more diplomatic language.
—
Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,684 registered users;
16 visitors (0 registered, 16 guests [including 4 identified bots]).
Forum time: 16:42 CEST (Europe/Vienna)

Pharmacokinetics: one of the magic arts of divination
whereby needles are stuck into dummies in an attempt
to predict profits.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5